Suven Life Sciences Share Price

NSE
260.01
+12.99 (5.13%)
SUVEN • 12 Jun, 2025 | 03:29 PM
BUY

1Y Annualised Return

158.12%

3Y Annualised Return

56.76%

5Y Annualised Return

55.19%

The current prices are delayed, login or Open Demat Account for live prices.

Suven Life Sciences SIP Return Calculator

Over the past

1 year
3 years
5 years

Total Investment of ₹65,00,000

Would have become ₹1,58,71,405 (+144.18%)

Daily SIP of 25,000 would have become 1,58,71,405 in 1 year with a gain of 93,71,405 (+144.18%)

Suven Life Sciences Stock Performance
Today’s Low - High
249.00
271.72
249.00
271.72
52 Week Low - High
95.20
271.72
95.20
271.72

Open

250.00

Prev. Close

247.02

Total Traded Value

89.33 Cr

View details of Market Depth
Suven Life Sciences Fundamental

Market Cap (in crs)

5,682.35

Face Value

1

Turnover (in lacs)

8,933.32

Key Metrics
Qtr Change %
New 52W High today
129.8
Dividend yield 1yr %
0

Suven Life Sciences Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Suven Life Sciences Quarterly Revenue

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
1.47 Cr
1.61 Cr
2.57 Cr
1.01 Cr
2.39 Cr

Suven Life Sciences Yearly Revenue

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
17.55 Cr
32.82 Cr
21.99 Cr
17.16 Cr
21.23 Cr
28.45 Cr

Suven Life Sciences Quarterly Net Profit/Loss

Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
-43.94 Cr
-39.12 Cr
-49.64 Cr
-28.04 Cr
-26.54 Cr

Suven Life Sciences Yearly Net Profit/Loss

Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
-160.74 Cr
-105.08 Cr
-118.27 Cr
-122 Cr
-72.15 Cr
-94.22 Cr
Suven Life Sciences Result Highlights
  • Suven Life Sciences Ltd reported a 105.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a decline of 18.8%.

  • Its expenses for the quarter were down by 19.2% QoQ and 4.6% YoY.

  • The net profit decreased 32.2% QoQ and decreased 4.0% YoY.

  • The earnings per share (EPS) of Suven Life Sciences Ltd declined at 1.2 during Q4FY25.

    Read more

Data Source: BSE, Company announcements

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Suven Life Sciences shareholding Pattern

Promoter
70.3%
Foreign Institutions
0.2%
Domestic Institutions
0.1%
Public
29.5%
Promoter
70.3%
Foreign Institutions
0.3%
Mutual Funds
1%
Domestic Institutions
1.1%
Public
28.4%
Promoter
70.3%
Foreign Institutions
0.3%
Mutual Funds
1%
Domestic Institutions
1.1%
Public
28.3%
Promoter
70.3%
Foreign Institutions
0.4%
Mutual Funds
1%
Domestic Institutions
1.2%
Public
28.1%
Promoter
69.6%
Foreign Institutions
0.5%
Mutual Funds
1%
Domestic Institutions
1.1%
Public
28.8%
Promoter
69.6%
Foreign Institutions
0.5%
Domestic Institutions
0.2%
Public
29.8%

Suven Life Sciences Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
260.01
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
242.60
10Day EMA
235.70
12Day EMA
233.10
20Day EMA
221.20
26Day EMA
212.40
50Day EMA
186.50
100Day EMA
162.40
200Day EMA
144.70
5Day SMA
235.10
10Day SMA
237.20
20Day SMA
226.70
30Day SMA
200.90
50Day SMA
171.30
100Day SMA
146.30
150Day SMA
141.60
200Day SMA
141.40
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
1327193 Rs
3791566 Rs
Week Rs
714637 Rs
1742931 Rs
Month Rs
704915 Rs
1812158 Rs
Resistance & Support
260.43
Pivot
Resistance
First Resistance
271.86
Second Resistance
283.15
Third Resistance
294.58
Support
First Support
249.14
Second support
237.71
Third Support
226.42
Relative Strength Index
73.44
Money Flow Index
71.72
MACD
20.71
MACD Signal
21.86
Average True Range
14.22
Average Directional Index
43.68
Rate of Change (21)
41.53
Rate of Change (125)
64.32

Suven Life Sciences Latest News

05 JUN 2025 | Thursday

Suven Life Sciences Ltd - 530239 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

05 JUN 2025 | Thursday

Suven Life Sciences Ltd - 530239 - Shareholder Meeting / Postal Ballot-Outcome of EGM

04 JUN 2025 | Wednesday

Suven Life Sciences Ltd - 530239 - Additional Disclosure In The Notice Of Extra-Ordinary General Meeting (EGM) Of The Company

View More

Suven Life Sciences Company background

Founded in: 1989
Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider.The Company is a clinicalstage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, ProofofConcept (POC) studies.The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process RD, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from projectbased transactions into relationshipbased business.In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to partfinance the companys project for the manufacture of bulk drugs and drug intermediates and meet longterm working capital requirements totalling to Rs 6.43 cr. During 19992000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad.During 200001, the company has registered a most remarkable record. The total sales of the company during 200001 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year.During the financial year ended 31 March 2014, Suvens Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 201415.During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNSbased programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suvens discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management.In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a headlice product with sales potential estimated at US35 million. In 201314, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 201415. During FY2015, Suvens lead clinical candidate SUVN502 has successfully completed Phase 1b clinical trial thus paving the way for the copound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/ each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.During FY15, the Companys main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.During FY2017, the company has spent Rs. 6973 lakhs on innovative RD in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets. During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose.In FY2018, the company has spent Rs 6,390 lakhs on innovative RD in CNS therapies accounting for 10% on sales.The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA.During the FY 20182019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies.In 201819, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN502, Masupirdine. In 201920, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.

As of 12 Jun, 2025 | 03:29 PM, Suven Life Sciences Ltd share price is ₹260.6 . The stock opened at ₹250 and had closed at ₹247 the previous day. During today’s trading session, Suven Life Sciences Ltd share price moved between ₹249.00 and ₹271.72, with an average price for the day of ₹260.00. Over the last 52 weeks, the stock has recorded a low of ₹95.20 and a high of ₹271.72. In terms of performance, Suven Life Sciences Ltd share price has increased by 75.4% over the past six months and has increased by 158.12% over the last year.

Read More

Suven Life Sciences FAQs

Suven Life Sciences share price is ₹260.01 in NSE and ₹260 in BSE as on 12/6/2025.

Suven Life Sciences share price in the past 1-year return was 158.11. The Suven Life Sciences share hit a 1-year low of Rs. 95.2 and a 1-year high of Rs. 271.72.

The market cap of Suven Life Sciences is Rs. 5682.35 Cr. as of 12/6/2025.

The PE ratios of Suven Life Sciences is 0 as of 12/6/2025.

The PB ratios of Suven Life Sciences is 7.11 as of 12/6/2025

The Mutual Fund Shareholding in Suven Life Sciences was 0.01% at the end of 12/6/2025.

You can easily buy Suven Life Sciences shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Please be aware that Suven Life Sciences stock prices are subject to continuous fluctuations due to various factors.

Open Demat Account
+91 -

Open Demat Account
+91 -